Utama › Mieloma Pelbagai › Missouri
Kajian klinikal Mieloma Pelbagai di Missouri
27 kajian untuk Mieloma Pelbagai sedang mencari peserta di lokasi di Missouri.
Bandar di Missouri
Teks kajian rasmi (Bahasa Inggeris)
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- Washington University School Of Medicine, St Louis
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07589634A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Washington University School of Medicine, St Louis
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT04973605A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, St Louis
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07073547A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Washington University School Of Medicine, St Louis
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT04634552A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- MidAmerica Cancer Care, Kansas City
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05552222A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Washington University School Of Medicine, St Louis
Mengambil pesertaFasa 4
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05201781Collection of Tissue Samples for Cancer Research
- Washington University - St. Louis, St Louis
Mengambil pesertaKajian pemerhatian
2 Months · Semua jantina · Dikemas kini 16 Sep 2026 · NCT00900198Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Washington University School of Medicine, St Louis
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT06297226A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Washington University School of Medicine, St Louis
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06980480A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, St Louis
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Ogo 2026 · NCT07681596A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Bridgeton
- GSK Investigational Site, Springfield
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT07227311MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- American Oncology Partners, P.A. Dba MidAmerica Cancer Care, Belton
- MIVA Medical, Independence
- Kansas City VA Medical Center, Kansas City
- dan 1 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Ogo 2026 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- dan 19 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT04566328Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, St Louis
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Ogo 2026 · NCT07764978Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
- Washington University School of Medicine, St Louis
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT06483100A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Washington University/Siteman Cancer Center, St Louis
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT07284758Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
- Washington University School of Medicine, St Louis
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Jul 2026 · NCT07200089Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
- Washington University School of Medicine, St Louis
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Jul 2026 · NCT06340646Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
- Washington University School of Medicine, St Louis
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Jul 2026 · NCT06185751Integrated Cancer Repository for Cancer Research
- Saint Luke's Cancer Institute, East, Kansas City
- Saint Luke's Cancer Institute, Kansas City
- Saint Luke's Cancer Institute, Kansas City North, Kansas City
- dan 3 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT0201269964Cu-LLP2A for Imaging Hematologic Malignancies
- Washington University School of Medicine, St Louis
Mengambil pesertaFasa awal 1Sukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Jun 2026 · NCT06636175Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Saint Louis Cancer and Breast Institute-Ballwin, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- dan 21 lagi
Mengambil pesertaFasa 3
Semua umur · Semua jantina · Dikemas kini 10 Jun 2026 · NCT05561387Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
- Washington University School of Medicine, St Louis
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Jun 2026 · NCT07200102An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
- Washington University School of Medicine, St Louis
Mengambil peserta
Umur 18 hingga 99 · Semua jantina · Dikemas kini 1 Jun 2026 · NCT07226934Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Washington University /ID# 266972, St Louis
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 12 Mei 2026 · NCT06896916Post-Op Pain Control for Prophylactic Intramedullary Nailing.
- Saint Louis University, St Louis
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Apr 2026 · NCT03823534Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
- Washington University School of Medicine, St Louis
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Mac 2026 · NCT06623630Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.